
const pages = [
  { 
    title: "Abstract",
    content: `Alzheimer's Disease (AD) remains a challenge in neurodegenerative disorders, 
    characterized by progressive cognitive decline and memory impairment. Current therapeutic 
    options are limited, primarily focusing on symptomatic relief rather than addressing the 
    underlying pathophysiology. The advent of CRISPR (Clustered Regularly Interspaced Short 
    Palindromic Repeats) gene editing technology has ignited renewed hope for developing 
    targeted genetic interventions. This review explores the application of CRISPR in 
    modulating genetic risk factors associated with AD, elucidating its potential for gene 
    editing, and addressing ethical implications surrounding its use. By reviewing recent 
    advances and ongoing studies, this paper aims to provide a comprehensive overview of the 
    prospects of CRISPR-based therapies in the context of Alzheimer’s Disease.

    Keywords- (CRISPR Alzheimer's Disease Gene Editing Neurodegeneration
    Genetic Therapy)
 `
  },
  { 
    title: "Introduction",
    content: `Alzheimer's Disease (AD) is the most prevalent form of dementia, 
    affecting millions worldwide. The disease is characterized by distinct 
    neuropathological features, including the accumulation of amyloid-beta plaques 
    and hyperphosphorylated tau proteins, which lead to neurodegeneration and 
    cognitive impairment. Genetic factors contribute significantly to the risk 
    of developing AD, particularly mutations in genes such as APP, PSEN1, and 
    PSEN2, as well as the presence of the APOE ε4 allele. CRISPR technology, a 
    revolutionary tool for precise gene editing, offers unprecedented potential to 
    target and modify genes associated with Alzheimer’s Disease. This paper examines 
    the pathophysiology of AD, the mechanisms of CRISPR, recent advancements in the 
    field, and ethical considerations, providing a roadmap for future research and 
    therapeutic applications. `
  },
  {
    title: "Chapter 1: The Pathophysiology of Alzheimer's Disease",
    content: `Alzheimer’s Disease was first identified by Alois Alzheimer in 1906 when 
    he described the clinical and pathological features of a patient named Auguste Deter.
    Over the years, research has shifted from purely descriptive studies to molecular 
    and genetic investigations, leading to significant advancements in understanding 
    the disease's underlying mechanisms. This shift has led to significant 
    advancements in our understanding of the underlying mechanisms of the disease. 
    A central tenet in AD research is the amyloid hypothesis.  The amyloid hypothesis 
    posits that the accumulation of amyloid-beta peptides in the brain is a central event 
    in the pathogenesis of AD. Amyloid precursor protein (APP) is cleaved by secretases, 
    resulting in the formation of toxic oligomers and insoluble fibrils. These amyloid-beta 
    aggregates disrupt synaptic function, activate neuroinflammatory pathways, and 
    ultimately lead to neuronal cell death. Tau is a microtubule-associated protein that 
    stabilizes neuronal microtubules. In AD, tau becomes hyperphosphorylated, leading 
    to the formation of neurofibrillary tangles. The presence of these tangles correlates 
    strongly with cognitive decline, making tau pathology a critical area of research.
    
    AD is characterized by a progressive loss of synapses, which are the communication 
    points between neurons. This synaptic dysfunction is thought to be a key contributor 
    to cognitive decline. In addition to synaptic loss, neuroinflammation plays a 
    significant role in the progression of AD. Neuroinflammation plays a dual role in AD.
    While it can be protective, chronic neuroinflammation contributes to the progression 
    of the disease. Activated microglia release pro-inflammatory cytokines, which can 
    exacerbate neuronal damage and promote further amyloid deposition. 
    Familial Alzheimer’s Disease (AD) is typically associated with early-onset 
    cases and is caused by mutations in genes such as APP, PSEN1, and PSEN2. 
    In contrast, sporadic AD, which is the more common form of the disease, often 
    involves the APOE ε4 allele, a significant risk factor for developing Alzheimer’s 
    later in life. Understanding these genetic influences is crucial for developing 
    targeted therapies, as they provide insights into the mechanisms driving both
    familial and sporadic forms of the disease.
`
  },
  {
    title: "Chapter 2: CRISPR Technology Overview",
    content: `CRISPR technology was discovered as a bacterial immune response 
    to viruses. The system consists of a Cas9 nuclease and a guide RNA (gRNA) 
    that directs Cas9 to specific DNA sequences. Once targeted, Cas9 induces 
    double-strand breaks, allowing for gene editing through repair mechanisms. 
    Cas12 is a next-generation CRISPR enzyme that offers enhanced specificity and 
    efficiency compared to Cas9. Its unique properties allow for more accurate targeting 
    and reduced off-target effects, making it a valuable tool for therapeutic applications. 
    Base editing is a revolutionary approach that allows for the conversion of one DNA base 
    pair into another without causing double-strand breaks. This precision makes it an 
    ideal method for correcting point mutations associated with genetic diseases, including 
    those linked to Alzheimer’s. Gene knockout models have been instrumental in elucidating 
    the role of specific genes in AD. For instance, studies have utilized CRISPR to knock out 
    APP in mouse models, leading to reduced amyloid plaque formation and improved cognitive 
    outcomes. These findings underscore the potential of gene editing to modulate AD pathology.
    CRISPR technology holds promise for correcting mutations in genes like PSEN1, which are 
    implicated in familial AD. Correcting these mutations in patient-derived iPSCs has shown
    potential for restoring normal cellular function, opening pathways for therapeutic 
    interventions. Modulating the expression of risk genes, particularly APOE, is another 
    promising application of CRISPR. Recent studies have demonstrated that reducing APOE 
    ε4 expression can mitigate amyloid accumulation in AD models, suggesting a 
    potential therapeutic target.`
  },
  {
    title: "Chapter 3:  Animal Models of Alzheimer's Disease",
    content: `Transgenic mouse models have been a cornerstone of AD research. CRISPR 
    allows for the creation of precise genetic modifications in these models, enabling 
    researchers to study the effects of specific gene alterations on AD pathology and 
    behavior. Behavioral assessments are critical for evaluating the cognitive function 
    of transgenic mice. Common tests include the Morris water maze and the Y-maze, 
    which assess learning and memory capabilities. These tests help correlate
    genetic modifications with functional outcomes.`
  },
   {
    title: "Chapter 4: Human Studies and iPSCs",
    content: `Induced pluripotent stem cells (iPSCs) are derived from adult 
    somatic cells and can differentiate into any cell type, including neurons.
    This technology allows researchers to model AD in vitro, providing a 
    platform for studying disease mechanisms and testing potential therapies.
    Using CRISPR to edit genes in iPSCs derived from AD patients enables the 
    exploration of disease mechanisms at the cellular level. This approach 
    facilitates drug screening and the identification of novel therapeutic targets.
    The translation of CRISPR research into clinical applications is ongoing. 
    Clinical trials are beginning to evaluate the safety and efficacy of CRISPR-based 
    therapies for genetic disorders, including those related to Alzheimer’s Disease.`
  },
   {
    title: "Chapter 5: Ethical Considerations in CRISPR Applications",
    content: `One of the primary concerns with CRISPR technology is the potential 
    for off-target effects, which could lead to unintended genetic modifications. 
    Rigorous testing and validation are essential to ensure the safety of CRISPR 
    applications in humans. The permanence of genetic modifications raises questions 
    about long-term effects on individuals and their descendants. Ethical considerations 
    regarding the long-term consequences of gene editing are crucial for guiding 
    research and clinical applications. Germline editing involves making changes to 
    the DNA of embryos, raising significant ethical concerns. The implications for 
    future generations and the potential for unintended consequences necessitate careful 
    consideration and regulation. As CRISPR technology advances, ensuring equitable access 
    to therapies is vital. Disparities in healthcare and access to cutting-edge treatments 
    could exacerbate existing inequalities, emphasizing the need for inclusive policies.`
  },
   {
    title: "Chapter 6 : Future Directions in CRISPR and Alzheimer’s Research",
    content: `Developing effective delivery mechanisms for CRISPR components is critical 
    for successful therapeutic applications. Nanoparticle-based delivery systems are being 
    investigated to improve the targeting and efficiency of gene editing in the brain. 
    Combining CRISPR with other therapeutic modalities, such as pharmacological agents 
    or immunotherapies, may enhance treatment outcomes. Research into multimodal approaches
    is essential for developing comprehensive AD therapies. CRISPR technology can be 
    integrated into personalized medicine strategies, allowing for tailored therapies
    based on an individual's genetic profile. This approach holds great promise for 
    improving therapeutic efficacy in AD treatment.
    One of the major challenges associated with CRISPR technology is the risk 
    of off-target effects, where the Cas9 enzyme edits unintended DNA sequences. 
    To mitigate this risk, researchers are actively developing strategies such as:
    Improved gRNA design: The design of guide RNAs can significantly impact 
    specificity. Computational tools and experimental validation are used to 
    identify gRNAs with minimal off-target potential.
    Modified Cas9 enzymes: Engineered variants of Cas9, such as Cas9-nickases and
    base editors, can reduce off-target effects by introducing single-stranded
    breaks or altering specific nucleotides without causing double-strand breaks.
    High-throughput sequencing: Next-generation sequencing techniques can be used 
    to identify and assess off-target editing sites, allowing for optimization
    of CRISPR systems.

    Delivering CRISPR components to the brain remains a significant hurdle. 
    Strategies being explored include:
    Nanoparticle-based delivery: Nanoparticles can encapsulate CRISPR
    components and facilitate their transport across the blood-brain barrier.
    Viral vectors: Lentiviral and adeno-associated viral vectors can be used 
    to deliver CRISPR components to neurons.
    Focused ultrasound: This non-invasive technique can temporarily open 
    the blood-brain barrier, allowing for increased drug delivery.
    
    The development and application of CRISPR technology for Alzheimer's
    disease raise important ethical considerations, including:
    Consent and autonomy: Ensuring that individuals with Alzheimer's disease or 
    their caregivers provide informed consent for genetic editing.
    Long-term implications: Assessing the potential long-term consequences of 
    genetic modifications, both for the individual and for future generations.
    Genetic enhancement: Addressing the ethical implications of using CRISPR 
    to enhance cognitive function or prevent Alzheimer's in individuals 
    without a genetic predisposition.
    A robust regulatory framework is essential to ensure the safe and 
    ethical development and use of CRISPR-based therapies. This framework 
    should address issues such as clinical trials, patient safety, and data privacy.`
  },
   {
    title: "Conclusion",
    content: `CRISPR gene editing offers a promising avenue for addressing the 
    complex challenges of Alzheimer's Disease. By targeting genetic risk factors 
    and modulating disease-related pathways, CRISPR has the potential to revolutionize 
    the treatment landscape. However, careful consideration of ethical implications, safety 
    concerns, and delivery challenges is essential for the successful translation of 
    CRISPR-based therapies into clinical practice. Continued research and development 
    are crucial for unlocking the full potential of CRISPR in the fight against
    Alzheimer's Disease.`
  },
   {
    title: "References",
    content: `Alzheimer's Association. (2023). Alzheimer's Disease Facts and Figures. 
    https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf
    
    Jackman, S.A., & Craddock, N.C. (2019). CRISPR/Cas9 gene editing: 
    A potential therapeutic strategy for Alzheimer's disease. 
    Journal of Molecular Biology, 431(18), 3721-3732.
    
    Lin, Y., & Liu, D. (2021). CRISPR-Cas9 gene editing for Alzheimer's disease: 
    Challenges and opportunities. Neuropharmacology, 186, 108312.
    
    Park, J.H., & Kim, J.S. (2022). CRISPR-Cas9 gene editing for Alzheimer's disease: 
    Current status and future perspectives. Molecular Neurobiology, 59(1), 1-10.
    
    Ran, F.A., et al. (2013). Genome engineering using the CRISPR-Cas9 system.
    Nature Protocols, 8(11), 2281-2290.
    
    Safi, K., & Langer, R. (2021). Delivery of CRISPR-Cas9 systems to the brain.
    Advanced Materials, 33(4), 2006058.

    Wu, Y., et al. (2020). Reducing off-target effects of CRISPR-Cas9-mediated 
    genome editing. Trends in Biotechnology, 38(1), 10-24.

    Cong, L., Ran, A., Cox, D., Lin, S., Gootenberg, J.S., Habibian, M.T., ... & 
    Zhang, F. (2013). Multiplex genome engineering by CRISPR-Cas systems. 
    Cell, 153(4), 1148-1155.
    
    Doudna, J.A., & Charpentier, E. (2014). The new frontier of genome engineering
    with CRISPR-Cas9. Science, 346(6213), 1258096.

    Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., ... & 
    Church, G.M. (2013). RNA-guided human genome engineering via CRISPR-Cas9.
    Science, 339(6121), 823-826.
   
   Huang, Z., & Zhang, Y. (2023). CRISPR-Cas9 gene editing for Alzheimer's disease:
   A review. Journal of Molecular Neuroscience, 73(2), 225-235.

   Li, X., et al. (2023). CRISPR-Cas9 gene editing for Alzheimer's disease:
   Progress and challenges. Frontiers in Aging Neuroscience, 15, 1013.
   
   Wang, Y., et al. (2023). CRISPR-Cas9 gene editing in Alzheimer's disease:
   A review. Neurobiology of Aging, 119, 109-118.
   
   Greely, H.T. (2016). The ethics of gene editing. Science, 352(6287), 812-813.
   
   Knoepfler, D.S. (2017). The ethics of gene editing. Nature Biotechnology,
   35(1), 4-5.
   
   Wyss-Coray, T. (2018). Gene editing: A double-edged sword for Alzheimer's disease.
   Nature Medicine, 24(1), 12-14.
`
  }
];

class FlipBook {
  constructor() {
    this.currentPage = 0;
    this.pageContainer = document.getElementById('page-container');
    this.titleElement = document.getElementById('chapter-title');
    this.contentElement = document.getElementById('page-text');
    this.pageNumberElement = document.getElementById('page-number');
  }

  render() {
    // Start transition
    this.pageContainer.classList.add('page-transition');
    
    setTimeout(() => {
      // Update content
      this.titleElement.textContent = pages[this.currentPage].title;
      this.contentElement.textContent = pages[this.currentPage].content;
      this.pageNumberElement.textContent = this.currentPage + 1;
      
      // End transition
      this.pageContainer.classList.remove('page-transition');
    }, 300);
  }

  next() {
    if (this.currentPage < pages.length - 1) {
      this.currentPage++;
      this.render();
    }
  }

  prev() {
    if (this.currentPage > 0) {
      this.currentPage--;
      this.render();
    }
  }
}

// Initialize book
const book = new FlipBook();
document.addEventListener('DOMContentLoaded', () => book.render());
